Mark H Yazer1, Darrell J Triulzi. 1. Division of Transfusion Medicine, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Abstract
PURPOSE OF REVIEW: Limitations in donor availability for stem cell or organ transplantation require that ABO-incompatible donors be used. Crossing ABO lines can have immune consequences characterized by immediate or delayed hemolysis. RECENT FINDINGS: The use of peripheral blood as a stem cell source has essentially eliminated the risk for ABO-mediated hemolysis during infusion. Delayed red cell engraftment is expected after a major ABO-incompatible transplant and may be associated with pure red cell aplasia. The incidence of hemolysis associated with minor ABO incompatibility, the passenger lymphocyte syndrome, is waning because anti-B-cell immunosuppressive therapy is increasingly a component of graft versus host disease prophylaxis. The impact of ABO mismatching on stem cell recipient survival remains an area of active investigation. Although major ABO-incompatible organs are not used routinely for transplantation, minor ABO-incompatible organs are frequently used to meet the demand for organs. Passenger lymphocyte syndrome in this setting is a common complication, and has now been observed with every organ type and increasingly with non-ABO antibodies. Hemolysis can occur, but it is uncommonly severe. SUMMARY: ABO-mismatched donors are commonly used for transplantation, and immune hemolysis remains the main complication. Clinicians must be vigilant in order to recognize hemolysis and implement appropriate therapy.
PURPOSE OF REVIEW: Limitations in donor availability for stem cell or organ transplantation require that ABO-incompatible donors be used. Crossing ABO lines can have immune consequences characterized by immediate or delayed hemolysis. RECENT FINDINGS: The use of peripheral blood as a stem cell source has essentially eliminated the risk for ABO-mediated hemolysis during infusion. Delayed red cell engraftment is expected after a major ABO-incompatible transplant and may be associated with pure red cell aplasia. The incidence of hemolysis associated with minor ABO incompatibility, the passenger lymphocyte syndrome, is waning because anti-B-cell immunosuppressive therapy is increasingly a component of graft versus host disease prophylaxis. The impact of ABO mismatching on stem cell recipient survival remains an area of active investigation. Although major ABO-incompatible organs are not used routinely for transplantation, minor ABO-incompatible organs are frequently used to meet the demand for organs. Passenger lymphocyte syndrome in this setting is a common complication, and has now been observed with every organ type and increasingly with non-ABO antibodies. Hemolysis can occur, but it is uncommonly severe. SUMMARY:ABO-mismatched donors are commonly used for transplantation, and immune hemolysis remains the main complication. Clinicians must be vigilant in order to recognize hemolysis and implement appropriate therapy.
Authors: H J Lee; A Gulbis; L De Padua Silva; C Hosing; I Khouri; M de Lima; R E Champlin; S O Ciurea Journal: Bone Marrow Transplant Date: 2008-03-17 Impact factor: 5.483
Authors: Willy A Flegel; Susan T Johnson; Margaret A Keller; Ellen B Klapper; Hanh M Khuu; Joann M Moulds; Axel W Seltsam; Gary Stack; Maryse St-Louis; Christopher A Tormey; Franz F Wagner; Christof Weinstock; Mark H Yazer; Gregory A Denomme Journal: Blood Transfus Date: 2013-10-18 Impact factor: 3.443
Authors: Scott T Avecilla; Steven M Marionneaux; Tyler D Leiva; Jo-Ann Tonon; Virgil T Chan; Christine Moung; Richard C Meagher; Peter Maslak Journal: Transfusion Date: 2015-09-23 Impact factor: 3.157
Authors: Hamilton C Tsang; Annie N Samraj; Ryan J Morse; Niklas Krumm; John R Hess; Monica B Pagano Journal: Blood Transfus Date: 2019-06-05 Impact factor: 3.443
Authors: Joshua R Peck; Elmahdi A Elkhammas; Feng Li; Peter P Stanich; Nicholas Latchana; Sylvester Black; Anthony Michaels Journal: Exp Clin Transplant Date: 2014-07-31 Impact factor: 0.945